Tricida (TCDA) Stock Price, News & Analysis

Company Overview

Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.11 to $0.19
• 52-Week Range: N/A
• Volume: 31.13 million shs
• Average Volume: 17.62 million shs
• Market Capitalization: $6.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TCDA Stock Analysis - Frequently Asked Questions

How were Tricida's earnings last quarter?

Tricida, Inc. (NASDAQ:TCDA) released its earnings results on Monday, November, 8th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by $0.09.

When did Tricida IPO?

Tricida (TCDA) raised $175 million in an IPO on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.

What other stocks do shareholders of Tricida own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tricida investors own include Sorrento Therapeutics (SRNE), Alibaba Group (BABA), NIO (NIO), Pfizer (PFE), Energy Transfer (ET), Teladoc Health (TDOC) and Sesen Bio (SESN).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 5/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TCDA
• CIK: 1595585
• Web: www.tricida.com
• Phone: (415) 429-7800
• Fax: N/A
• Employees: 57
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$176.57 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -103.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.87
• Quick Ratio: 4.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 55,670,000
• Free Float: 35,851,000
• Market Cap: $6.01 million
• Optionable: Not Optionable
• Beta: 0.22